Funck, Jr. Robert E. 4
4 · ABBOTT LABORATORIES · Filed May 14, 2024
Insider Transaction Report
Form 4
Funck Robert E
Vice President, Controller
Transactions
- Exercise/Conversion
Common shares without par value
2024-05-10$47.00/sh+10,097$474,559→ 221,438 total - Sale
Common shares without par value
2024-05-10$104.57/sh−10,097$1,055,819→ 211,341 total - Exercise/Conversion
Option (right to buy)
2024-05-10−10,097→ 45,000 totalExercise: $47.00From: 2016-02-20Exp: 2025-02-19→ Common Shares (10,097 underlying)
Holdings
- 500(indirect: By Daughter)
Common shares without par value
- 20,000(indirect: By Trust)
Common shares without par value
- 18,765(indirect: By Trust)
Common shares without par value
- 20,000(indirect: By Trust)
Common shares without par value
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
- [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024.
- [F4]The reporting person disclaims beneficial ownership of all securities held by his daughter.
- [F5]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.